Grover NS, Park SI (2015) Novel targeted agents in hodgkin and non-Hodgkin lymphoma therapy. Pharmaceuticals (Basel, Switzerland) 8:607–636

Article  CAS  PubMed  Google Scholar 

Wang L, Qin W, Huo YJ, Li X, Shi Q, Rasko JEJ et al (2020) Advances in targeted therapy for malignant lymphoma. Signal Transduct Target Ther 5:15

Article  PubMed  PubMed Central  Google Scholar 

Abodunrin FO, Akinyemi OA, Ojo AS, Elleissy Nasef K, Haupt T, Oduwole A et al (2022) Racial disparities in survival among non-Hodgkin lymphoma patients: an analysis of the SEER database (2007–2015). Cureus 14:e25867

PubMed  PubMed Central  Google Scholar 

Thandra KC, Barsouk A, Saginala K, Padala SA, Barsouk A, Rawla P (2021) Epidemiology of non-Hodgkin’s lymphoma. Med Sci (Basel, Switzerland) 9(1):5

Google Scholar 

Liu W, Wu M, Xie Y, Zhang C, Ping L, Feng F et al (2021) Autologous hematopoietic stem cell transplantation with inadequate stem cell dose in patients with non-Hodgkin lymphoma. Leuk Lymphoma 62:323–329

Article  CAS  PubMed  Google Scholar 

Shanbhag S, Ambinder RF (2018) Hodgkin lymphoma: a review and update on recent progress. CA Cancer J Clin 68:116–132

Article  PubMed  Google Scholar 

Moskowitz C (2016) Novel agents and strategies in transplant-eligible patients with relapsed and refractory Hodgkin lymphoma. Hematol Am Soc Hematol Educ Program 2016:331–338

Article  Google Scholar 

Shah GL, Moskowitz CH (2018) Transplant strategies in relapsed/refractory Hodgkin lymphoma. Blood 131:1689–1697

Article  CAS  PubMed  PubMed Central  Google Scholar 

Siegel RL, Miller KD, Jemal A (2016) Cancer statistics, 2016. CA Cancer J Clin 66:7–30

Article  PubMed  Google Scholar 

Bhatt VR (2016) Allogeneic stem cell transplantation for non-Hodgkin lymphoma. Curr Hematol Malig Rep 11:196–207

Article  PubMed  Google Scholar 

Armand P, Engert A, Younes A, Fanale M, Santoro A, Zinzani PL et al (2018) Nivolumab for relapsed/refractory classic hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II CheckMate 205 Trial. J Clin Oncol 36:1428–1439

Article  CAS  PubMed  PubMed Central  Google Scholar 

Peggs KS, Mackinnon S, Linch DC (2005) The role of allogeneic transplantation in non-Hodgkin’s lymphoma. Br J Haematol 128:153–168

Article  PubMed  Google Scholar 

Dreger P (2021) Allogeneic stem cell transplant in non-Hodgkin lymphomas: still an indication? Hematol Oncol 39(Suppl 1):100–103

Article  PubMed  Google Scholar 

Schimmer AD, Jamal S, Messner H, Keating A, Meharchand J, Huebsch L et al (2000) Allogeneic or autologous bone marrow transplantation (BMT) for non-Hodgkin’s lymphoma (NHL): results of a provincial strategy. Ontario BMT Network, Canada. Bone Marrow Transpl 26:859–864

Article  CAS  Google Scholar 

Berg T, Mian HS, Meyer RM (2020) Registry data and conditioning therapy for allogeneic hematopoietic cell transplant and lymphoma. JAMA Oncol 6:989–991

Article  PubMed  Google Scholar 

Thomson KJ, Morris EC, Bloor A, Cook G, Milligan D, Parker A et al (2009) Favorable long-term survival after reduced-intensity allogeneic transplantation for multiple-relapse aggressive non-Hodgkin’s lymphoma. J Clin Oncol 27:426–432

Article  PubMed  Google Scholar 

Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E et al (2014) Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 32:3059–3068

Article  PubMed  PubMed Central  Google Scholar 

Vigorito AC, Campregher PV, Storer BE, Carpenter PA, Moravec CK, Kiem HP et al (2009) Evaluation of NIH consensus criteria for classification of late acute and chronic GVHD. Blood 114:702–708

Article  CAS  PubMed  PubMed Central  Google Scholar 

Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA et al (1974) Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 18:295–304

Article  CAS  PubMed  Google Scholar 

Jones RJ, Lee KS, Beschorner WE, Vogel VG, Grochow LB, Braine HG et al (1987) Venoocclusive disease of the liver following bone marrow transplantation. Transplantation 44:778–783

Article  CAS  PubMed  Google Scholar 

Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V et al (2009) Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transpl 15:1628–1633

Article  Google Scholar 

Bader P, Niethammer D, Willasch A, Kreyenberg H, Klingebiel T (2005) How and when should we monitor chimerism after allogeneic stem cell transplantation? Bone Marrow Transpl 35:107–119

Article  CAS  Google Scholar 

Carreras E, Dufour C, Mohty M, Kröger N, editors. The EBMT handbook: hematopoietic stem cell transplantation and cellular therapies. Cham (CH): Springer Copyright 2019, The Editor(s) (if applicable) and The Author(s). 2019.

Ko SH, Lee JH, Lee JH, Park HS, Choi EJ, Seol M et al (2018) Allogeneic hematopoietic cell transplantation for lymphoma: baseline and posttransplant prognostic factors. Leuk Lymphoma 59:1829–1839

Article  PubMed  Google Scholar 

Lee JH, Lee JH, Kim DY, Seol M, Lee YS, Kang YA et al (2015) A phase II trial of fludarabine/melphalan 100 conditioning therapy followed by allogeneic hematopoietic cell transplantation for patients with lymphoma. Clin Lymphoma Myeloma Leuk 15:655–663

Article  PubMed  Google Scholar 

Giaccone L, Festuccia M, Zallio F, Sorasio R, Brunello L, Maffini E et al (2017) Long-term follow-up of allogeneic stem cell transplantation in relapsed/refractory Hodgkin lymphoma. Bone Marrow Transpl 52:1208–1211

Article  CAS  Google Scholar 

Spina F, Radice T, De Philippis C, Soldarini M, Di Chio MC, Dodero A et al (2019) Allogeneic transplantation for relapsed and refractory Hodgkin lymphoma: long-term outcomes and graft-versus-host disease-free/relapse-free survival. Leuk Lymphoma 60:101–109

Article  PubMed  Google Scholar 

Jeon YW, Yoon S, Min GJ, Park SS, Park S, Yoon JH et al (2019) Risk factors predicting graft-versus-host disease and relapse-free survival after allogeneic hematopoietic stem cell transplantation in relapsed or refractory non-Hodgkin’s lymphoma. Ann Hematol 98:1743–1753

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dodero A, Patriarca F, Milone G, Sarina B, Miceli R, Iori A et al (2017) Allogeneic stem cell transplantation for relapsed/refractory B cell lymphomas: results of a multicenter phase II prospective trial including rituximab in the reduced-intensity conditioning regimen. Biol Blood Marrow Transpl 23:1102–1109

Article  CAS  Google Scholar 

Yoon JH, Jeon YW, Lee SE, Cho BS, Eom KS, Kim YJ et al (2017) Allogeneic stem cell transplantation using lymphoablative rather than myeloablative conditioning regimen for relapsed or refractory lymphomas. Hematol Oncol 35:17–24

Article  CAS  PubMed  Google Scholar 

Hamadani M, Saber W, Ahn KW, Carreras J, Cairo MS, Fenske TS et al (2013) Impact of pretransplantation conditioning regimens on outcomes of allogeneic transplantation for chemotherapy-unresponsive diffuse large B cell lymphoma and grade III follicular lymphoma. Biol Blood Marrow Transpl 19:746–753

Article  Google Scholar 

Hamadani M, Saber W, Ahn KW, Carreras J, Cairo MS, Fenske TS et al (2013) Allogeneic hematopoietic cell transplantation for chemotherapy-unresponsive mantle cell lymphoma: a cohort analysis from the center for international blood and marrow transplant research. Biol Blood Marrow Transpl 19:625–631

Article  Google Scholar 

Saini NY, Saliba RM, Rondon G, Maadani F, Popat U, Hosing CM et al (2019) Impact of donor type and melphalan dose on allogeneic transplantation outcomes for patients with lymphoma. Biol Blood Marrow Transpl 25:1340–1346

Article  CAS  Google Scholar 

Bachanova V, Burns LJ, Wang T, Carreras J, Gale RP, Wiernik PH et al (2015) Alternative donors extend transplantation for patients with lymphoma who lack an HLA matched donor. Bone Marrow Transpl 50:197–203

Article  CAS  Google Scholar